---
document_datetime: 2025-02-03 15:30:38
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trazimera-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: trazimera-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.6782956
conversion_datetime: 2025-12-15 06:11:59.448421
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Trazimera

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IAIN/0021            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 12/01/2024                          |                                             | Annex II and PL                  |                                                                                                                   |
| R/0020               | Renewal of the marketing authorisation.                                                                                    | 26/01/2023                          | 20/03/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                       | Trazimera in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0019            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/10/2022 | 20/03/2023 | SmPC                  |                                                                                                                                                         |
| PSUSA/3010/ 202109 | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/06/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                       |
| IB/0017/G          | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 22/11/2021 | 20/12/2021 | SmPC, Annex II and PL |                                                                                                                                                         |
| N/0016             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/10/2021 | 20/12/2021 | PL                    |                                                                                                                                                         |
| IB/0014            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/03/2021 | 20/12/2021 | SmPC and PL           |                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                    | 05/03/2021   | 20/12/2021   | Annex II and PL   | IA/0015                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|------------------------|
| IB/0013 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                     | 11/01/2021   | 20/12/2021   | SmPC and PL       |                        |
| II/0011 | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                              | 05/03/2020   | 22/01/2021   | Annex II          |                        |
| IB/0010 | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                            | 04/02/2020   | 22/01/2021   | SmPC and PL       |                        |
| N/0012  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                 | 02/12/2019   | 22/01/2021   | PL                |                        |
|         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient Change in test procedure for the | 11/10/2019   | n/a          |                   | IA/0009/G B.II.e.3.a - |

<div style=\"page-break-after: always\"></div>

|                    | immediate packaging of the finished product - Minor changes to an approved test procedure                                                                                                                                                                    |            |            |                        |                                                                                                                                           |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/3010/ 201809 | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                    | 29/05/2019 | 31/07/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/3010/201809. |
| IB/0008            | B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation                                                                                                                                          | 26/06/2019 | n/a        |                        |                                                                                                                                           |
| IB/0007            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 11/04/2019 | 31/07/2019 | SmPC, Labelling and PL |                                                                                                                                           |
| II/0005            | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                     | 14/03/2019 | 31/07/2019 | SmPC, Labelling and PL |                                                                                                                                           |
| II/0002            | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method               | 24/01/2019 | n/a        |                        |                                                                                                                                           |
| IB/0003            | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a                                                                                                                                                            | 30/10/2018 | n/a        |                        |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|           | biological/immunological medicinal product                                 |            |            |                        |           |
|-----------|----------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| IB/0004   | B.I.z - Quality change - Active substance - Other                          | 29/10/2018 | n/a        |                        | variation |
| IAIN/0001 | A.1 - Administrative change - Change in the name and/or address of the MAH | 14/09/2018 | 31/07/2019 | SmPC, Labelling and PL |           |